Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (ICK)
Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1081 HV
- VUMedical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Advanced solid malignancy
- minimum age 18 years
- indication for palliative treatment
- measurable disease with at least one lesion accessable for biopsy
Exclusion Criteria:
- Cardiovascular conditions including congestive heartfailure NYHA class >2
- recent myocardial infarction or uncontrolled coronary artery disease
- cardiac arrhythmias requiring anti-arrhythmic therapy
- uncontrolled hypertension
- uncontrolled infections
- serious non-healing wound, ulcer or bone fracture
- pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Kinase inhibitor
Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
|
50 mg once daily, oral use, 14 days
400 mg, twice daily, oral use, 14 days
150 mg once daily, oral use, 14 days
10 mg once daily, oral use, 14 days
1250 mg once daily, oral use, 14 days
100 mg once daily, oral use, 14 days
800 mg once daily, oral use, 14 days
960 mg twice daily, oral use, 15-21 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
concentrations of intratumoral kinase inhibitors upon 2 weeks of treatment
Time Frame: 2 weeks
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
kinase inhibitor concentrations in plasma, serum and PBMC's upon 2 weeks of treatment
Time Frame: 2 weeks
|
2 weeks
|
|
intra-dermal kinase inhibitor concentrations upon 2 weeks of treatment
Time Frame: 2 weeks
|
2 weeks
|
|
To determine per patient whether 2 weeks of treatment with kinase inhibitors induces significant change of phosphoproteomic profiles in tumor tissue
Time Frame: 2 weeks
|
2 weeks
|
|
To determine per patient whether 2 weeks of treatment with kinase inhibitors induces significant change of kinase activity in tumor tissue
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: H.M.W. Verheul, MD, PhD, VU medical center Amsterdam
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Sorafenib
- Sunitinib
- Everolimus
- Dasatinib
- Lapatinib
- Vemurafenib
Other Study ID Numbers
Other Study ID Numbers
- 2011/128
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.